Picture of Sartorius Stedim Biotech SA logo

DIM — Sartorius Stedim Biotech SA News Story

0.000.00%
fr flag iconLast trade - 00:00
HealthcareSpeculativeLarge CapHigh Flyer

UBS upbeat on European pharma, but flags caution on AstraZeneca

** UBS sees a positive macro backdrop for major European
pharma companies in 2024 with strong cashflows and attractive
valuations
    ** The broker initiates British GSK  GSK.L , French Sanofi
 SASY.PA  and German Merck  MRCG.DE  at "buy", citing their
significant scope for a positive 2024 momentum
    ** It also notes the attractive valuation of Switzeland's
Novartis  NOVN.S  ("buy"), saying its mid-term EPS growth
above-consensus "justifies a premium"
    ** The brokerage expects weak U.S. dollar to act as an
earnings drag for Denmark's Novo Nordisk  NOVOb.CO  ("neutral"),
a high US$ earner, without impacting its underlying growth
    ** But it starts UK-based AstraZeneca  AZN.L  with "sell",
flagging concerns about its exposure to U.S. Medicare Part D
reform that may result in price pressures and sales growth
decrease

 (Reporting by Anastasiia Kozlova)
 ((Anastasiia.Kozlova@thomsonreuters.com))

Recent news on Sartorius Stedim Biotech SA

See all news